Johnson & Johnson (NYSE:JNJ) Shares Bought by Hendershot Investments Inc.

Hendershot Investments Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,899 shares of the company’s stock after purchasing an additional 3,221 shares during the period. Johnson & Johnson makes up approximately 4.4% of Hendershot Investments Inc.’s investment portfolio, making the stock its 3rd largest holding. Hendershot Investments Inc.’s holdings in Johnson & Johnson were worth $23,507,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in JNJ. Price T Rowe Associates Inc. MD grew its stake in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. FMR LLC grew its stake in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. GQG Partners LLC lifted its holdings in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after acquiring an additional 1,805,632 shares in the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 over the last 90 days. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $168.31 on Tuesday. The stock’s 50-day simple moving average is $176.07 and its 200 day simple moving average is $171.13. The company has a market cap of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Barclays assumed coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price on the stock. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday. Sanford C. Bernstein cut their price target on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Morgan Stanley cut their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 6th. Finally, Bank of America cut their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $181.75.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.